NOTES PAYABLE (Details Narrative) - Aspire Biopharma Inc [Member] - USD ($) |
Dec. 31, 2024 |
Dec. 30, 2024 |
Oct. 02, 2024 |
Sep. 27, 2024 |
|---|---|---|---|---|
| Debt interest rate | 20.00% | 20.00% | 20.00% | 20.00% |
| Principal amount | $ 279,878 | $ 40,625 | $ 62,500 | $ 1,066,391 |
| Gross proceeds | $ 2,500,000 | $ 2,500,000 | $ 2,500,000 | $ 2,500,000 |
| Debt interest stated percentage | 5.00% | 5.00% | 5.00% | 5.00% |
| Debt unamortized discount | $ 46,646 | $ 8,125 | $ 12,500 | $ 213,278 |
| X | ||||||||||
- Definition Face (par) amount of debt instrument at time of issuance. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The average effective interest rate during the reporting period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Contractual interest rate for funds borrowed, under the debt agreement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, after accumulated amortization, of debt discount. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The cash inflow from the additional capital contribution to the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|